Off-label oritavancin treatment outcome and molecular characterization of a vancomycin- and linezolid-resistant <i>Enterococcus faecium</i> causing liver abscesses-Reference-Cited by-同舟云学术

Off-label oritavancin treatment outcome and molecular characterization of a vancomycin- and linezolid-resistant Enterococcus faecium causing liver abscesses

Published:2024-01-16 Issue:3 Volume:79 Page:689-691
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Mazzitelli Maria¹^ORCID,Scaglione Vincenzo¹^ORCID,Cattarin Leda²,Franchin Elisa³,Stano Paola³,Paci Lorenzo⁴,Coppi Marco⁴,Rossolini Gian Maria⁴^ORCID,Mengato Daniele⁵,Calò Lorenzo²,Cattelan Anna Maria¹

Affiliation:

1. Infectious and Tropical Diseases Unit, Padua University Hospital , Padua , Italy

2. Nephrology Unit, Padua University Hospital , Padua , Italy

3. Microbiology and Virology Unit, Padua University Hospital , Padua , Italy

4. Department of Experimental and Clinical Medicine, University of Florence , Florence , Italy

5. Hospital Pharmacy Unit, Padua University Hospital , Padua , Italy

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/jac/article-pdf/79/3/689/56796832/dkad410.pdf

Reference10 articles.

1. Oritavancin activity tested against molecularly characterized staphylococci and enterococci displaying elevated linezolid MIC results;Mendes;Antimicrob Agents Chemother,2016

2. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: a systematic review;Thomas;Int J Antimicrob Agents,2020

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Head-to-head comparison of multi-dose oritavancin and dalbavancin for complicated infections: A propensity score-matched analysis;International Journal of Antimicrobial Agents;2024-06